文献速递血液净化与透析慢性肾脏病

质子泵抑制剂与组胺-2受体拮抗剂在血液透析患者中的髋部骨折风险

Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-09-27

该研究基于美国肾脏数据系统,纳入2009至2014年血液透析依赖患者的髋部骨折事件,匹配10倍对照,发现质子泵抑制剂(PPI)使用与髋部骨折风险升高相关(调整OR 1.19),而组胺-2受体拮抗剂无此关联。

要点

  • PPI使用与血液透析患者髋部骨折风险升高独立相关。
  • 组胺-2受体拮抗剂使用未显示与髋部骨折风险相关。
  • 低、中、高PPI使用比例亚组中关联均持续存在。

核心结论

  • 在血液透析的终末期肾病患者中,PPI使用而非组胺-2受体拮抗剂与髋部骨折事件相关。

研究设计与样本

  • 使用美国肾脏数据系统,识别2009至2014年血液透析患者的髋部骨折事件,按指数日期匹配10倍对照,从Medicare Part D索赔中识别PPI和组胺-2受体拮抗剂使用,采用逻辑回归及多重插补估计OR和95%CI。
  • 共纳入4551例病例和45510例对照。

主要发现

  • PPI使用与髋部骨折风险升高相关(调整OR 1.19;95%CI 1.11-1.28)。
  • 低、中、高PPI使用亚组的调整OR分别为1.16(95%CI 1.06-1.27)、1.21(95%CI 1.11-1.31)、1.19(95%CI 1.08-1.31)。
  • 组胺-2受体拮抗剂使用与髋部骨折风险无显著关联。

临床怎么用

  • 对血液透析患者应审慎评估PPI使用的必要性,尤其关注髋部骨折风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: An association between proton pump inhibitor (PPI) use and hip fracture risk has been described in the general population, where the primary causative hypothesis focuses on impaired gastrointestinal calcium absorption. The impact of acid suppressor use on hip fracture risk in a high-risk subset, patients with ESKD requiring hemodialysis, is unknown and could help further distinguish the reason for higher susceptibility among PPI users. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using the US Renal Data System, we identified all hip fracture events recorded between 2009 and 2014 among patients dependent on hemodialysis. Eligible cases were matched on index date with ten controls. We identified PPI and histamine-2 receptor antagonist use from Medicare Part D claims covering 3 years before the index date and stratified according to proportion of days covered by filled prescriptions. Using logistic regression with multiple imputation for missing data, we estimated unadjusted and multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs). RESULTS: We studied 4551 cases and 45,510 controls. Patients were older, more likely to be female and white, and had shorter dialysis vintage; fewer were obese. A larger proportion of patients had any prior PPI (70% versus 63%) or histamine-2 receptor antagonist (25% versus 23%) use. Use of PPI was associated with higher risk of hip fracture (adjusted OR, 1.19; 95% CI, 1.11 to 1.28). This association remained within subgroups of low, moderate, and high PPI use, yielding adjusted ORs of 1.16 (95% CI, 1.06 to 1.27), 1.21 (95% CI, 1.11 to 1.31), and 1.19 (95% CI, 1.08 to 1.31), respectively. CONCLUSIONS: Among patients with ESKD on hemodialysis, PPIs and not histamine-2 receptor antagonists were associated with hip fracture events.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Vangala C, Niu J, Lenihan CR, et al. Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis. Clin J Am Soc Nephrol. 2018. PMID: 30262672. doi:10.2215/CJN.02190218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。